Treatment of KRAS mutant lung cancer remains a clinical challenge, despite the recent approval of the first KRAS targeted inhibitor sotorasib for KRAS G12C mutant NSCLC based on the promising activity in the CodeBreak100 trial [34]. The gene discussed is KRAS; the disease is lung carcinoma.